|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US5223426A
(en)
|
1988-12-15 |
1993-06-29 |
T Cell Sciences, Inc. |
Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5582996A
(en)
|
1990-12-04 |
1996-12-10 |
The Wistar Institute Of Anatomy & Biology |
Bifunctional antibodies and method of preparing same
|
|
ATE207080T1
(de)
|
1991-11-25 |
2001-11-15 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
|
DE69309472T2
(de)
|
1992-01-23 |
1997-10-23 |
Merck Patent Gmbh, 64293 Darmstadt |
Fusionsproteine von monomeren und dimeren von antikörperfragmenten
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
DK1621554T4
(da)
|
1992-08-21 |
2012-12-17 |
Univ Bruxelles |
Immunoglobuliner blottet for lette kæder
|
|
US5795572A
(en)
|
1993-05-25 |
1998-08-18 |
Bristol-Myers Squibb Company |
Monoclonal antibodies and FV specific for CD2 antigen
|
|
US5747654A
(en)
|
1993-06-14 |
1998-05-05 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant disulfide-stabilized polypeptide fragments having binding specificity
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
GB9625640D0
(en)
|
1996-12-10 |
1997-01-29 |
Celltech Therapeutics Ltd |
Biological products
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
EP0983303B1
(en)
|
1997-05-21 |
2006-03-08 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
|
EP1958962A3
(en)
|
1997-06-12 |
2013-05-01 |
Novartis International Pharmaceutical Ltd. |
Artificial antibody polypeptides
|
|
US6849258B1
(en)
|
1997-07-18 |
2005-02-01 |
Universite Catholique De Louvain |
LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
|
|
GB9720054D0
(en)
|
1997-09-19 |
1997-11-19 |
Celltech Therapeutics Ltd |
Biological products
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
|
US6541611B1
(en)
|
1999-06-18 |
2003-04-01 |
Universite Catholique De Louvain |
LO-CD2b antibody
|
|
EP1332209B1
(en)
|
2000-09-08 |
2009-11-11 |
Universität Zürich |
Collections of repeat proteins comprising repeat modules
|
|
EP1243276A1
(en)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Elongated and multiple spacers containing activatible prodrugs
|
|
US20050048512A1
(en)
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
CA2463879C
(en)
|
2001-10-25 |
2012-12-04 |
Genentech, Inc. |
Glycoprotein compositions
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
JP3975850B2
(ja)
|
2002-07-25 |
2007-09-12 |
富士ゼロックス株式会社 |
画像処理装置
|
|
DK1545613T3
(da)
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
|
AU2003256038A1
(en)
|
2002-08-30 |
2004-03-19 |
Ramot At Tel Aviv University Ltd. |
Self-immolative dendrimers releasing many active moieties upon a single activating event
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
WO2004043493A1
(en)
|
2002-11-14 |
2004-05-27 |
Syntarga B.V. |
Prodrugs built as multiple self-elimination-release spacers
|
|
JP5356648B2
(ja)
|
2003-02-20 |
2013-12-04 |
シアトル ジェネティックス， インコーポレイテッド |
抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
JP2006526414A
(ja)
*
|
2003-06-02 |
2006-11-24 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
脱免疫化抗ｃｄ３抗体
|
|
GB0315450D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
GB0315457D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
ES2551439T5
(es)
|
2003-07-01 |
2018-11-08 |
Ucb Biopharma Sprl |
Fragmentos Fab de anticuerpos modificados
|
|
US20050164301A1
(en)
|
2003-10-24 |
2005-07-28 |
Avidia Research Institute |
LDL receptor class A and EGF domain monomers and multimers
|
|
WO2006028936A2
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
AU2006232287B2
(en)
|
2005-03-31 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
DK3248613T3
(da)
|
2005-07-18 |
2022-03-14 |
Seagen Inc |
Beta-glucuronid-lægemiddel-linkerkonjugater
|
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
|
ES2593484T3
(es)
|
2007-03-29 |
2016-12-09 |
Genmab A/S |
Anticuerpos biespecíficos y métodos de producción de los mismos
|
|
BRPI0820229A2
(pt)
|
2007-11-28 |
2017-05-09 |
A Stevenson Cheri |
conjugados de análogos de fumagilina biodegradáveis biocompatíveis
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
JP6157046B2
(ja)
|
2008-01-07 |
2017-07-05 |
アムジェン インコーポレイテッド |
静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
|
|
WO2010027797A1
(en)
|
2008-08-26 |
2010-03-11 |
Macrogenics Inc. |
T-cell receptor antibodies and methods of use thereof
|
|
US20100152725A1
(en)
|
2008-12-12 |
2010-06-17 |
Angiodynamics, Inc. |
Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
|
|
AU2010254013A1
(en)
|
2009-05-28 |
2011-11-24 |
Mersana Therapeutics, Inc. |
Polyal drug conjugates comprising variable rate-releasing linkers
|
|
DE102010012915A1
(de)
|
2010-03-26 |
2011-09-29 |
Schaeffler Technologies Gmbh & Co. Kg |
Vorrichtung und Verfahren zur Ermittlung eines Schädigungszustands eines Radlagers
|
|
EP2553019A1
(en)
|
2010-03-26 |
2013-02-06 |
Mersana Therapeutics, Inc. |
Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
|
|
WO2011130324A1
(en)
|
2010-04-13 |
2011-10-20 |
Medimmune, Llc |
Fibronectin type iii domain-based multimeric scaffolds
|
|
HRP20241208T1
(hr)
|
2010-04-20 |
2024-11-22 |
Genmab A/S |
Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
|
|
ES2758994T3
(es)
|
2010-11-05 |
2020-05-07 |
Zymeworks Inc |
Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
|
|
SG11201401422VA
(en)
|
2011-10-27 |
2014-09-26 |
Genmab As |
Production of heterodimeric proteins
|
|
UY34542A
(es)
|
2011-12-23 |
2013-07-31 |
Mersana Therapeutics Inc |
?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
|
|
WO2014008375A1
(en)
|
2012-07-05 |
2014-01-09 |
Mersana Therapeutics, Inc. |
Terminally modified polymers and conjugates thereof
|
|
CN102827281B
(zh)
|
2012-08-03 |
2014-05-28 |
无锡傲锐东源生物科技有限公司 |
抗cd2蛋白单克隆抗体及其用途
|
|
CN105026430B
(zh)
|
2012-11-28 |
2025-03-25 |
酵活英属哥伦比亚有限公司 |
工程化免疫球蛋白重链-轻链对及其用途
|
|
WO2014093379A1
(en)
|
2012-12-10 |
2014-06-19 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
|
CA2892863C
(en)
|
2012-12-10 |
2022-03-15 |
Mersana Therapeutics, Inc. |
Polymeric scaffold based on phf for targeted drug delivery
|
|
WO2014093640A1
(en)
|
2012-12-12 |
2014-06-19 |
Mersana Therapeutics,Inc. |
Hydroxy-polmer-drug-protein conjugates
|
|
KR102211837B1
(ko)
|
2013-01-14 |
2021-02-03 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
WO2014116846A2
(en)
*
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
|
CN105283201B
(zh)
*
|
2013-03-14 |
2019-08-02 |
斯克利普斯研究所 |
靶向剂抗体偶联物及其用途
|
|
ES2821753T3
(es)
|
2013-03-15 |
2021-04-27 |
Lilly Co Eli |
Procedimientos de producción de Fab y de anticuerpos biespecíficos
|
|
JP6594855B2
(ja)
|
2013-03-15 |
2019-10-23 |
ゼンコア インコーポレイテッド |
ヘテロ二量体タンパク質
|
|
KR102236367B1
(ko)
|
2013-07-26 |
2021-04-05 |
삼성전자주식회사 |
DARPin을 포함하는 이중 특이 키메라 단백질
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
PE20171324A1
(es)
|
2014-11-26 |
2017-09-11 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
|
|
US20160176969A1
(en)
|
2014-11-26 |
2016-06-23 |
Xencor, Inc. |
Heterodimeric antibodies including binding to cd8
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
AU2016225968B2
(en)
|
2015-03-05 |
2020-07-23 |
Think Surgical, Inc. |
Methods for locating and tracking a tool axis
|
|
WO2016146702A1
(en)
*
|
2015-03-16 |
2016-09-22 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Trispecific binding molecules for treating hbv infection and associated conditions
|
|
BR112017023943A2
(pt)
|
2015-05-08 |
2018-07-31 |
Xencor, Inc. |
anticorpos heterodimêricos que ligam cd3 e antígenos de tumor
|
|
WO2017013136A1
(en)
|
2015-07-20 |
2017-01-26 |
Scil Proteins Gmbh |
Novel binding proteins based on di-ubiquitin muteins and methods for generation
|
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
|
WO2017124002A1
(en)
|
2016-01-13 |
2017-07-20 |
Compass Therapeutics Llc |
Multispecific immunomodulatory antigen-binding constructs
|
|
JP7542438B2
(ja)
*
|
2017-11-21 |
2024-08-30 |
ノバルティス アーゲー |
腫瘍関連抗原に対する三重特異性結合分子及びその使用
|
|
WO2020052692A2
(en)
|
2018-12-04 |
2020-03-19 |
Novartis Ag |
Binding molecules against cd3 and uses thereof
|
|
JP7489407B2
(ja)
*
|
2019-05-21 |
2024-05-23 |
ノバルティス アーゲー |
Ｃｄ１９結合分子及びその使用
|
|
CN118994397A
(zh)
*
|
2019-05-21 |
2024-11-22 |
诺华股份有限公司 |
针对bcma的三特异性结合分子及其用途
|
|
CA3199095A1
(en)
*
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
IL302412A
(en)
*
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
|